# Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer

> **NCT01047358** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 206 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Aromasin
- **DRUG:** Aromasin

## Key facts

- **NCT ID:** NCT01047358
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 206 (ACTUAL)
- **Last updated:** 2015-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01047358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01047358, "Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01047358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*